

## 15

-continued

Capsules	
Components	Composition Per Unit (mg)
Shell	
Iron oxide, red (C.I. No. 77491, EC No. E 172)	0.123
Iron oxide, yellow (C.I. No. 77492, EC No. E 172)	0.123
Iron oxide, black (C.I. No. 77499, EC No. E 172)	0.245
Titanium dioxide	1.540
Gelatin	74.969
Total Tablet Mass	342.00

The formulation is manufactured, e.g., as described in Formulation Example 4.

## Formulation Example 6

Hard Gelatine Capsule	
Components	Composition Per Unit (mg)
Valsartan [=active ingredient]	80.00
Sodium lauryl sulphate	0.60
Magnesium stearate	1.30
Povidone	12.50
Crospovidone	13.00
Microcrystalline cellulose	21.10
Total Tablet Mass	130.00

## Formulation Example 7

A hard gelatin capsule, comprising as active ingredient, e.g., (S)—N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine, can be formulated, e.g., as follows:

Components	Composition Per Unit (mg)
(1) Valsartan	80.00
(2) Microcrystalline cellulose	110.0
(3) Polyvidone K30	45.2
(4) Sodium lauryl sulfate	1.2

## 16

-continued

Components	Composition Per Unit (mg)
(5) Crospovidone	26.0
(6) Magnesium stearate	2.6

Components (1) and (2) are granulated with a solution of components (3) and (4) in water. The components (5) and (6) are added to the dry granulate and the mixture is filled into size 1 hard gelatin capsules.

All publications and patents mentioned herein are incorporated by reference in their entirety as if set forth in full herein.

What is claimed is:

1. A pharmaceutical composition comprising:

(i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof;

(ii) the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester or (2R,4S)-5-biphenyl-4-yl-4(3-carboxy-propionyl amino)-2-methyl-pentanoic acid or a pharmaceutically acceptable salt thereof; and

(iii) a pharmaceutically acceptable carrier;

wherein said (i) AT 1-antagonist valsartan or pharmaceutically acceptable salt thereof and said (ii) NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester or (2R,4S)-5-biphenyl-4-yl-4(3-carboxy-propionyl amino)-2-methyl-pentanoic acid or pharmaceutically acceptable salt thereof, are administered in combination in about a 1:1 ratio.

2. The pharmaceutical composition of claim 1, wherein said (i) AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof and said (ii) NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester or (2R,4S)-5-biphenyl-4-yl-4(3-carboxy-propionyl amino)-2-methyl-pentanoic acid or pharmaceutically acceptable salt thereof are administered in amounts effective to treat hypertension or heart failure.

3. The pharmaceutical composition of claim 1 wherein (ii) said NEP inhibitor is N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester.

4. The pharmaceutical composition of claim 3 in the form of a capsule or tablet.

\* \* \* \* \*